Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.65 |
| ▸ | TP53 | P04637 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 9/20 | 0.61 |
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522655 | 1.00 | MAPT (0.65) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL25920614 | 0.82 | MAPT (0.62) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL24125223 | 0.81 | MAPT (0.68) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL25920612 | 0.77 | MAPT (0.58) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL25922050 | 0.76 | MAPT (0.65) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL24124923 | 0.74 | KMT2A (0.51) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL25920622 | 0.74 | MAPT (0.55) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL25920890 | 0.74 | NPC1 (0.63) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL9368758 | 0.73 | HTT (0.73) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL24125206 | 0.73 | MAPT (0.70) | MAPTSMN1; SMN2TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | MAPT 4492/4885SMN1; SMN2 4270/4885TP53 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.